Trevi Therapeutics (TRVI) Share-based Compensation (2018 - 2026)

Trevi Therapeutics' Share-based Compensation history runs 9 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 81.37% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $6.2 million, a 51.4% increase from a year earlier, with the FY2025 full-year figure at $11.5 million, up 69.12% from the prior year.
• Share-based Compensation grew to $2.2 million in Q1 2026 per TRVI's latest filing, from $1.3 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $2.2 million in Q1 2026 and bottomed at $501000.0 in Q4 2022.
• The 5-year median for Share-based Compensation is $737000.0 (2022), against an average of $909647.1.
• Across the five-year window, Share-based Compensation tumbled 30.2% in 2022 and surged 112.64% in 2024, its largest moves.
• Year by year, Share-based Compensation stood at $501000.0 in 2022, then increased by 6.59% to $534000.0 in 2023, then jumped by 71.72% to $917000.0 in 2024, then surged by 47.22% to $1.3 million in 2025, then soared by 62.3% to $2.2 million in 2026.
• Per Business Quant, the three latest TRVI Share-based Compensation figures stand at $2.2 million (Q1 2026), $1.3 million (Q4 2025), and $1.2 million (Q3 2025).